Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
111,675,845
-
Share change
-
-5,808,724
-
Total reported value
-
$475,736,700
-
Put/Call ratio
-
118%
-
Price per share
-
$4.26
-
Number of holders
-
80
-
Value change
-
-$26,235,400
-
Number of buys
-
34
-
Number of sells
-
33
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2021
As of 30 Jun 2021,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
111,675,845 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, NEA Management Company, LLC, BAILLIE GIFFORD & CO, BAKER BROS. ADVISORS LP, Capital World Investors, PFM Health Sciences, LP, MORGAN STANLEY, Point72 Asset Management, L.P., Avoro Capital Advisors LLC, and JPMORGAN CHASE & CO.
This page lists
80
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.